72 percent of infants were found to be immunized against respiratory syncytial virus (RSV). Stephanie A. Irving, from Kaiser Permanente Center for Health Research in Portland, Oregon, and ...

In a recent study of a population of infants, published online May 6 in Pediatrics, 72% of infants were found to be immunized against respiratory syncytial virus (RSV). Nirsevimab administration ...

Ziresovir is the first antiviral to demonstrate significant clinical efficacy and long-term respiratory benefits in hospitalized infants under six months of age with respiratory syncytial virus.

A study presented at ESCMID Global 2025 has revealed that adults with respiratory syncytial virus-associated acute respiratory infection (RSV-ARI) face a 2.7-fold higher risk of death within one ...

Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting ...

The agency noted it is not an indication that respiratory virus activity has peaked and that such activity "is expected to continue for several more weeks." STOCK PHOTO/Getty Images Dr. John ...

Respiratory syncytial virus (RSV) is a common viral infection that may lead to serious complications in certain groups. Since 2023, vaccines are now available and are highly recommended ...

Respiratory syncytial virus (RSV) is a major cause of respiratory infections, particularly in infants, children under 5 years, and older adults. Its rapid spread makes RSV a serious public health ...

About AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) AREXVY contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with GSK ...

Respiratory syncytial virus (RSV) is a leading cause of severe illness in infants, with no effective treatment. Results of a phase 2 trial suggested that ziresovir may have efficacy in the ...

caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older and in individuals 50 through 59 who are at increased risk for LRTD caused by RSV. The data were presented as a ...

Respiratory syncytial virus (RSV) is a common virus that affects the throat, nose, and lungs. Symptoms include a runny nose, congestion, sneezing, wheezing, cough, and fever, and these are often ...